Streetbeat News

Products Services

INDP

Indaptus Therapeutics has started unrestricted enrollment for its Decoy20 Phase 1 trial, which involves weekly dosing. This development marks a significant step in the company's clinical trial process.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:03 pm

BCTX

BriaCell is progressing with its Phase 3 clinical trial for Bria-IMT™ in combination with an immune checkpoint inhibitor for metastatic breast cancer. The trial is active at 35 sites, with the primary endpoint being overall survival. Interim data analysis is planned at 144 events, potentially leading to full approval and marketing authorization. Patient enrollment is expected to complete by mid-2025, and no serious adverse events have been reported.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:56 am

LUCD

PAVM

Lucid Diagnostics has received a Notice of Allowance from the USPTO for a patent application covering its proprietary method using methylation of the Cyclin-A1 gene to detect esophageal precancer and cancer.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:55 am

BTAI

BioXcel Therapeutics announced that the Department of Defense has granted funds to the University of North Carolina to study BXCL501. The Phase 2a trial for efficacy and safety is expected to begin enrollment in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:51 am

BTCUSD

Mark Cuban praised Vice President Kamala Harris for her evolving understanding of cryptocurrency, particularly Bitcoin, and her efforts to protect digital asset holders. Cuban highlighted Harris's recognition of the app economy and her proposal for a new regulatory framework supporting digital assets.

Portfolio Pulse from Khyathi Dalal

October 15, 2024 | 11:49 am

RNAC

Cartesian Therapeutics announced positive results from its Phase 2b trial of Descartes-08 for treating Generalized Myasthenia Gravis, achieving its primary endpoint with significant improvements in patients. The company plans to discuss next steps with the FDA.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:47 am

ZENA

ZenaTech has launched the first US trial of its IQ Nano Drone, aimed at revolutionizing inventory management in the auto parts industry. This innovation could enhance efficiency and accuracy in inventory processes.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:44 am

CLYM

Climb Bio has completed its transition to focus on immune-mediated diseases and expects its cash runway to last through 2027, enabling the delivery of key value inflection points.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:44 am

NSPR

InspireMD has established its global headquarters in Miami, Florida, to support the anticipated U.S. launch of the CGuard Prime carotid stent system in 2025, pending approval.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:42 am

EPRX

Eupraxia has published Phase 2 data from its SPRINGBOARD trial, which evaluates EP-104IAR for treating knee osteoarthritis. This development could impact the company's stock, EPRX.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:41 am